-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4281 Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients with Chromosome 5 and 7 Abnormalities

Program: Oral and Poster Abstracts
Session: 617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster III
Hematology Disease Topics & Pathways:
Acute Myeloid Malignancies, AML, Research, Clinical Research, Diseases, Myeloid Malignancies
Monday, December 9, 2024, 6:00 PM-8:00 PM

Leora Boussi, MD1, Jan Philipp Bewersdorf, MD2, Yiwen Liu, MS3*, Rory M. Shallis, MD4, Luis E. Aguirre5*, Andrius Zucenka, MD6, Sylvain Garciaz, MD7*, Rebecca P. Bystrom, MD5, Daniel J. DeAngelo, MD, PhD8, Richard M Stone, MD9, Marlise R. Luskin, MD9, Jacqueline S. Garcia, MD9, Eric S. Winer, MD9, Evan Chen, MD10*, Martha Wadleigh, MD9, Kelly Ling, PA-C9*, Amer M. Zeidan, MBBS, MHS2, Aaron D. Goldberg1, Eytan M. Stein, MD11, Shai Shimony, MD9 and Maximilian Stahl, MD12

1Department of Medicine; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY
2Department of Internal Medicine, Section of Hematology, Yale School of Medicine - Yale Cancer Center, New Haven, CT
3Data Science, Dana-Farber Cancer Institute, Boston, MA
4Department of Internal Medicine, Section of Hematology, Yale School of Medicine - Yale Cancer Center, Killingworth, CT
5Dana-Farber Cancer Institute, Boston, MA
6Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
7Institut Paoli-Calmettes, MARSEILLE, France
8Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA
9Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
10Department of Medical Oncology, Dana-Farber Cancer Institute, Boston
11Department of Medicine; Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY
12Dana Farber Cancer Institute, Boston, MA

Background: Deletions in chromosome 7 (del(7)) are the most common individual cytogenetic abnormality conferring adverse risk in acute myeloid leukemia (AML). Adverse risk monosomy 5 and 5q deletions (-5/del(5q)) occur in up to 40% of clinically defined secondary AML. As these alterations are associated with poor outcomes, allogeneic stem cell transplant (alloSCT) is recommended for patients (pts) who achieve post-induction complete remission (CR). However, whether induction with intensive chemotherapy (IC) is superior to hypomethylating agent plus venetoclax (HMA+ven) is unclear. Hence, we performed a retrospective study in a large cohort comparing outcomes in pts with del(7)/del(7q) and/or -5/del(5q) treated with IC vs HMA+ven.

Methods: We included clinicopathological and molecular data from 1125 pts with newly diagnosed AML from 4 academic centers (MSKCC, DFCI, Yale, NCI in Lithuania) treated with 7+3 or CPX-351 (IC) vs HMA+ven. We defined molecular ontogeny as previously described (Lindsley, Blood 2015). The Kaplan-Meier method was used to estimate overall survival (OS). Log-rank test was used to compare OS between groups. Composite CR (cCR) was defined as CR+CR with incomplete count recovery (CRi).

Results: 228 pts (20%) had del(7)/del(7q) (n=140/228, 61%) and/or -5/del(5q) (n=145/228, 64%). Median age was 68 yrs (22, 92). Induction therapy was IC in 38% (86/228) and HMA+ven in 62% (142/228). Clinical and molecular characteristics differed between groups: HMA+ven-treated pts were older (median 72 vs 61 yrs, p<0.001) and more likely to harbor TP53 mutations (70% vs 37%; p<0.001) and complex karyotype (83% vs 64%; p<0.001); IC-treated pts had higher rates of prior MDS (30% vs 22%, p=0.16), HMA exposure (20% vs 10%, p=0.046), and RUNX1 (23% vs 10%; p=0.012), BCOR (10% vs 3%; p=0.048), RAS pathway (63% vs 29%; p<0.001), and secondary ontogeny mutations (56% vs 28%; p<0.001). cCR rates were comparable across IC and HMA+ven groups (40% vs 41%), with morphologic leukemia-free state rate of 5% vs 14%. In pts with minimal residual disease (MRD) assessment, MRD negativity was achieved in 17% (7/42) of IC- and 37% (22/59) of HMA+ven-treated pts. AlloSCT rates were higher after IC than HMA+ven (53% vs 18%, p<0.001). Relapse rates were lower in the IC group (35% vs 76%).

In the entire cohort (n=1125), median OS (mOS) was shorter with del(7)/del(7q) and/or -5/del(5q) than without [7.4 months (mos) (95% CI, 6.2-9.4) vs 27 mos (95% CI 22-32), p<0.001)]. Pts with del(7)/del(7q) and/or -5/del(5q) treated with IC had longer mOS compared to HMA+ven [10 mos (95% CI, 7.6-15) vs 6.1 mos (95% CI, 5.6-7.8), p=0.0032]. As HMA+ven-treated pts were older, subsequent OS comparison was focused on pts age 60-75, wherein IC-treated pts had comparable mOS to HMA+ven [7.6 mos (95% CI, 5.6-11) vs 6.4 mos (95% CI, 5.7-9.4), p=0.67]. The mOS for pts who received alloSCT was significantly longer compared to pts who did not [24 mos (95% CI 18-44) vs 5.5 mos (95% CI 4.4-6.1), p<0.0001]. However, mOS of pts undergoing alloSCT did not differ by pre-transplant IC vs HMA+ven [21 mos (95% CI, 16-51) vs 25 mos (95% CI, 18-NR), p=0.49].

Lastly, we evaluated the differential effect of the ontogeny of co-occurring mutations and treatment strategy on survival. Of all pts with del(7)/del(7q) and/or -5/del(5q), 18%, 25%, and 57% had co-mutations of de novo, secondary, and TP53 mutated ontogeny, respectively. Evaluation of each ontogeny by treatment revealed that with a secondary ontogeny defining co-mutation, mOS was longer in 30 IC- than 24 HMA+ven-treated pts [14 mos (95% CI 6.8-51) vs. 5.7 mos (95% CI 2.9-NR), p=0.045]. Conversely, with de novo ontogeny defining co-mutations, there was no difference in mOS between 24 IC- and 18 HMA+ven-treated pts [13 mos (95% CI 5.7-36) vs. 13 mos (95% CI 5.9-24), p=0.49]. In pts with TP53 co-mutations, mOS was comparable between 32 IC- and 98 HMA+ven-treated pts [8.3 mos (95% CI 6.2-16) vs. 6 mos (95% CI 5.1-8), p=0.11]. A multivariable analysis of predictors of survival will be presented at the ASH meeting.

Conclusions: In this large multicenter cohort, survival outcomes for pts with del(7)/del(7q) and/or -5/del(5q) were overall poor but improved with alloSCT. There was no difference in mOS following induction with IC vs HMA+ven in pts age 60-75 and in pts who had alloSCT after induction. There was also no difference in mOS following induction with IC vs HMA+ven in pts with a concomitant de novo ontogeny defining or TP53 co-mutation.

Disclosures: Shallis: Kura Oncology: Consultancy, Honoraria; Rigel: Consultancy, Honoraria; Servier: Consultancy, Honoraria, Other: Steering Commitee; Gilead Sciences, Inc: Consultancy, Honoraria. Zucenka: AbbVie: Consultancy, Honoraria, Other: travel expenses; Astellas: Consultancy, Honoraria; Pfizer: Consultancy; Johnson & Johnson: Consultancy, Honoraria, Other: travel expenses; Novartis: Consultancy, Honoraria, Other: travel expenses; Takeda: Other: travel expenses. Garciaz: Janssen: Consultancy, Honoraria; Imcheck Therapeutics: Consultancy; Servier: Consultancy, Honoraria; Sanofi: Consultancy, Other: travel grant; Abbvie: Consultancy, Honoraria, Other: Travel grant; BMS: Consultancy. DeAngelo: Daiichi-Sankyo, Fibrogen: Other: DSMB; AbbVie, Blueprint, GlycoMimetics, Novartis: Research Funding; Mt Sinai MPN Consortium: Other: Mt Sinai MPN Consortium; Amgen, Autolus, Blueprint, Gilead, Incyte, Jazz, Novartis, Pfizer, Servier, Takeda: Consultancy; Dana-Farber Cancer Institute: Current Employment. Stone: Epizyme: Consultancy; CTI Pharma: Consultancy; Cellularity: Consultancy; BerGenBio: Consultancy; AvenCell: Consultancy; Aptevo: Consultancy; AMGEN: Consultancy; Takeda: Consultancy; Hemavant: Consultancy; GSK: Consultancy; Jazz: Consultancy; Kura: Consultancy; Rigel: Consultancy; Syntrix: Consultancy. Luskin: Pfizer: Honoraria; KITE: Honoraria; Jazz: Honoraria; AbbVie: Research Funding; Novartis: Honoraria, Research Funding. Garcia: AbbVie: Consultancy, Research Funding; Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Taiho: Research Funding; Servier: Consultancy; Newave: Research Funding. Zeidan: Akeso Pharma: Consultancy, Honoraria; Karyopharm: Consultancy, Honoraria; Medus: Consultancy, Honoraria; Notable: Consultancy, Honoraria; Takeda: Consultancy, Honoraria, Research Funding; Faron: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Lava Therapeutics: Consultancy, Honoraria; BioCryst: Consultancy, Honoraria; Servier: Consultancy, Honoraria; Keros: Consultancy, Honoraria; Schroedinger: Consultancy, Honoraria; Geron: Consultancy, Honoraria, Research Funding; Bristol Myers Squibb/Celgene: Consultancy, Honoraria, Research Funding; Regeneron: Consultancy, Honoraria; Syndax: Consultancy, Honoraria; Shattuck Labs: Research Funding; Zentalis: Consultancy, Honoraria; Vinerx: Consultancy, Honoraria; Orum: Consultancy, Honoraria; ALX Oncology: Consultancy, Honoraria; Hikma: Consultancy, Honoraria; BeiGene: Consultancy, Honoraria; Sumitomo: Consultancy, Honoraria; Kyowa Kirin: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research Funding; Daiichi Sankyo: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Rigel: Consultancy, Honoraria; Chiesi: Consultancy, Honoraria; Astellas: Consultancy, Honoraria; Agios: Consultancy, Honoraria; Genentech: Consultancy, Honoraria; Kura: Consultancy, Honoraria, Research Funding; Gilead: Consultancy, Honoraria; Glycomimetics: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria, Research Funding; Astex: Research Funding; Epizyme: Consultancy, Honoraria; Amgen: Consultancy, Honoraria, Research Funding; Syros: Consultancy, Honoraria, Research Funding; Boehringer-Ingelheim: Consultancy, Honoraria; Otsuka: Consultancy, Honoraria, Research Funding; Taiho: Consultancy, Honoraria; Treadwell: Consultancy, Honoraria. Goldberg: Ikena Oncology: Consultancy; Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees; Molecular Partners: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Research Funding; Celularity: Research Funding; Daiichi Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees; Kura Oncology: Honoraria, Research Funding; Syndax Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Aprea: Research Funding; Aptose: Research Funding; AROG: Research Funding; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Consultancy, Membership on an entity's Board of Directors or advisory committees; DAVA Oncology: Honoraria. Stein: Genentech: Consultancy, Other: consulting fees; Gilead: Consultancy, Other: consulting fees; Abbvie: Consultancy, Other: consulting fees; Jazz Pharmaceuticals: Consultancy, Other: consulting fees; Astellas Pharmaceuticals: Consultancy, Other: consulting fees; Agios Pharmaceuticals: Consultancy, Other: consulting fees; AstraZeneca: Consultancy, Other: consulting fees; Daiichi Sankyo, Inc.: Consultancy, Other: consulting fees; Celgene: Consultancy, Other: consulting fees; Servier: Consultancy, Other: consulting fees. Stahl: Sierra Oncolgy: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; Sobi: Membership on an entity's Board of Directors or advisory committees; Kymera: Membership on an entity's Board of Directors or advisory committees; Rigel: Membership on an entity's Board of Directors or advisory committees; GSK: Membership on an entity's Board of Directors or advisory committees; Syndax: Membership on an entity's Board of Directors or advisory committees.

*signifies non-member of ASH